Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups.

doi:10.1158/1078-0432.CCR-24-1073

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Oct 2024

Bardia Aditya, Cortés Javier, Bidard François-Clément, Neven Patrick, Garcia-Sáenz José, Aftimos Phillipe, O'Shaughnessy Joyce, Lu Janice, Tonini Giulia, Scartoni Simona, Paoli Alessandro, Binaschi Monica, Wasserman Tomer, Kaklamani Virginia

Abstract excerpt

PURPOSE: Elacestrant significantly prolonged progression-free survival (PFS) with manageable safety versus standard-of-care (SOC) endocrine therapy (ET) in patients with estrogen receptor-positive (ER+), HER2- metastatic breast cancer and tumors harboring estrogen receptor 1 (ESR1) mutation following ET plus a cyclin-dependent kinase 4/6 inhibitor (ET+CDK4/6i). In patients with ESR1-mutated tumors, we evaluated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclin-Dependent Kinase 4

Share to Cyclin-Dependent Kinase 6

Share to Erb-b2 Receptor Tyrosine Kinases

Share to Estrogen Receptor alpha

Share to Neoplasm Metastasis

Share to Piperazines

Share to Receptors, Estrogen

Source

Open in PubMed Open full text

Identifiers

PMID: 39087959
DOI: 10.1158/1078-0432.CCR-24-1073
PMCID: PMC11443208

Genes

CDK4
ESR1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups.PMID 39087959Read ↗

Elacestrant in ESR1-mutant, endocrine-responsive metastatic breast cancer: should health authorities consider post hoc data to inform priority access?Semantic proximity Read ↗

CDK4/6 Inhibitor Efficacy in ESR1-Mutant Metastatic Breast Cancer.Semantic proximity Read ↗

The Value of Oral Selective Estrogen Receptor Degraders in Patients with HR-Positive, HER2-Negative Advanced Breast Cancer after Progression on ≥ 1 Line of Endocrine Therapy: Systematic Review and Meta-analysisSemantic proximity Read ↗

Elacestrant in metastatic breast cancer: current advancements and future perspectives.Semantic proximity Read ↗

Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast Cancer.Semantic proximity Read ↗

Design of SERENA-6, a phase III switching trial of camizestrant in ESR1 -mutant breast cancer during first-line treatmentSemantic proximity Read ↗

Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial.Semantic proximity Read ↗

Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy.Semantic proximity Read ↗

Novel oral selective estrogen receptor degraders (SERDs) to target hormone receptor positive breast cancer: elacestrant as the poster-child.Semantic proximity Read ↗

Elacestrant Plus Alpelisib in an ESR1 and PIK3CA Co-mutated and Heavily Pretreated Metastatic Breast Cancer: The First Case for Combination Efficacy and SafetySemantic proximity Read ↗

Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial.Semantic proximity Read ↗

ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.